
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
This Psychiatric Times® supplement provides a brief review of primarily recent literature on tardive dyskinesia, including signs and symptoms, risk factors and epidemiology, potential mechanisms, and screening and treatment.




